- Open
- 0.68
- High
- 0.70
- Low
- 0.65
- Close
- 0.70
- Change
- -0.03 (-3.70%)
- Volume
- 194,107
| 4 Aug 2026 | 10:30:00 | Holding(s) in Company |
| 31 Jul 2026 | 11:07:26 | Total Voting Rights |
| 29 Jul 2026 | 15:33:00 | Holding(s) in Company |
| 23 Jul 2026 | 09:25:44 | Grant of Director Share Options |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| 4 Aug 2026 | 10:30:00 | Holding(s) in Company |
| 31 Jul 2026 | 11:07:26 | Total Voting Rights |
| 29 Jul 2026 | 15:33:00 | Holding(s) in Company |
| 23 Jul 2026 | 09:25:44 | Grant of Director Share Options |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| 21 Jul 2026 |
| 17:23:38 |
| Holding(s) in Company |
| 29 Jun 2026 |
| Thalia Therapeutics goes clinical-stage overnight with Sanmirna acquisition |
| 24 Jun 2026 | AIM Market Roundup: Thalia Therapeutics, Novacyt, TMT Investments |
| 24 Jun 2026 | AIM movers: Thalia Therapeutics acquisition and Velocity Composites second half hit by business mix |
| 24 Jun 2026 | Thalia shares jump 20% on AML drug acquisition and £2.75m raise |
| 21 Jul 2026 |
| 17:23:38 |
| Holding(s) in Company |
| 29 Jun 2026 |
| Thalia Therapeutics goes clinical-stage overnight with Sanmirna acquisition |
| 24 Jun 2026 | AIM Market Roundup: Thalia Therapeutics, Novacyt, TMT Investments |
| 24 Jun 2026 | AIM movers: Thalia Therapeutics acquisition and Velocity Composites second half hit by business mix |
| 24 Jun 2026 | Thalia shares jump 20% on AML drug acquisition and £2.75m raise |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £295m | +0.4% | |
| £48m | -0.3% | |
| £40m | — | |
THATThalia Therapeutics PLC | £12m | +0.5% |
| £11m | +0.0% | |
| £11m | +2.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £295m | +0.4% | |
| £48m | -0.3% | |
| £40m | — | |
THATThalia Therapeutics PLC | £12m | +0.5% |
| £11m | +0.0% | |
| £11m | +2.0% |